- Home
- RPAY vs SLDB Comparison
RPAY vs SLDB Comparison
Compare RPAY & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- SLDB
- Stock Information
- Founded
- RPAY 2006
- SLDB 2013
- Country
- RPAY United States
- SLDB United States
- Employees
- RPAY N/A
- SLDB N/A
- Industry
- RPAY Business Services
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPAY Consumer Discretionary
- SLDB Health Care
- Exchange
- RPAY Nasdaq
- SLDB Nasdaq
- Market Cap
- RPAY 473.8M
- SLDB 433.0M
- IPO Year
- RPAY N/A
- SLDB 2018
- Fundamental
- Price
- RPAY $5.88
- SLDB $5.32
- Analyst Decision
- RPAY Buy
- SLDB Strong Buy
- Analyst Count
- RPAY 9
- SLDB 10
- Target Price
- RPAY $7.22
- SLDB $15.00
- AVG Volume (30 Days)
- RPAY 770.3K
- SLDB 787.2K
- Earning Date
- RPAY 11-11-2025
- SLDB 11-05-2025
- Dividend Yield
- RPAY N/A
- SLDB N/A
- EPS Growth
- RPAY N/A
- SLDB N/A
- EPS
- RPAY N/A
- SLDB N/A
- Revenue
- RPAY $310,367,000.00
- SLDB N/A
- Revenue This Year
- RPAY N/A
- SLDB N/A
- Revenue Next Year
- RPAY $9.47
- SLDB N/A
- P/E Ratio
- RPAY N/A
- SLDB N/A
- Revenue Growth
- RPAY 1.45
- SLDB N/A
- 52 Week Low
- RPAY $3.59
- SLDB $2.41
- 52 Week High
- RPAY $9.75
- SLDB $8.14
- Technical
- Relative Strength Index (RSI)
- RPAY 58.44
- SLDB 43.96
- Support Level
- RPAY $5.62
- SLDB $4.87
- Resistance Level
- RPAY $6.00
- SLDB $5.77
- Average True Range (ATR)
- RPAY 0.19
- SLDB 0.30
- MACD
- RPAY -0.01
- SLDB -0.03
- Stochastic Oscillator
- RPAY 71.03
- SLDB 47.89
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.